Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

44.20 USD -1.00 (-2.21%)
Official Closing Price Updated: 7:20 PM EST, Mar 8, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 412,600
Open 45.81
Bid (Size) 43.05 (1)
Ask (Size) 47.27 (1)
Prev. Close 45.20
Today's Range 43.67 - 47.24
52wk Range 13.77 - 71.50
Shares Outstanding 15,645,545
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast
From GlobeNewswire News Releases
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation
From GlobeNewswire News Releases

Performance

YTD
-15.41%
-15.41%
1 Month
-26.33%
-26.33%
3 Month
-4.74%
-4.74%
6 Month
+5.11%
+5.11%
1 Year
+51.68%
+51.68%

More News

Read More
BioXcel Therapeutics Appoints June Bray to Board of Directors
From GlobeNewswire News Releases
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation
From GlobeNewswire News Releases
BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary
From GlobeNewswire News Releases
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms
From GlobeNewswire News Releases
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
From GlobeNewswire News Releases
BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
From GlobeNewswire News Releases
BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
BioXcel's BXCL501 Lower Dose Shows Statistical Significance On Agitation Scales
Tags Small Cap FDA Market News
From Benzinga
BioXcel Therapeutics Starts Testing BXCL501 In Mid-Stage Delirium-Related Agitation Study
Tags General BTAI Biotech
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.